

## Author index

### Volume 268 (1997)

- Alvarez, V., see Ricós, C. **268**, 73
- Bellometti, S., Cecchetti, M., Galzigna, L., Mud pack therapy in osteoarthritis. Changes in serum levels of chondrocyte markers **268**, 101
- Bruunshuus, I., see Cornelis, R. **268**, S75
- Bruunshuus, I., see Olesen, H. **268**, S5
- Büttner, C., see Schmidt, H.H.-J. **268**, 41
- Campbell, J.M., see Reglinski, J. **268**, 85
- Cecchetti, M., see Bellometti, S. **268**, 101
- Cornelis, R., Fuentes-Arderiu, X., Bruunshuus, I., Templeton, D., International Union of Pure and Applied Chemistry Clinical Chemistry Division, Commission on Toxicology (C-TOX), Commission on Nomenclature, Properties and Units (C-NPU) and International Federation of Clinical Chemistry, Scientific Division Committee on Nomenclature, Properties and Units (C-NPU). Properties and Units in the Clinical Laboratory Sciences. IX. Properties and Units in Trace Elements (IUPAC-IFCC Technical report 1997) **268**, S75
- Cowan, D., see Olesen, H. **268**, S5
- Cynober, L., see Minet, R. **268**, 121
- Den Tandt, W.R., Scharpé, S., Plasma methylumbelliferyl-tetra-N-acetyl-chitotetraoside hydrolase: further study of its characteristics as a chitinase and comparison with its activity on Remazol Brilliant Violet carboxymethyl chitin **268**, 107
- Dowling, R.H., see Thomas, L.A. **268**, 61
- French, G.L., see Thomas, L.A. **268**, 61
- Fuentes-Arderiu, X., see Cornelis, R. **268**, S75
- Galzigna, L., see Bellometti, S. **268**, 101
- Genschel, J., see Schmidt, H.H.-J. **268**, 41
- Haas, R.E., see Schmidt, H.H.-J. **268**, 41
- Hernández, A., see Ricós, C. **268**, 73
- Hill, G., see Olesen, H. **268**, S5
- Holmskov, U., see Jensen, C.H. **268**, 1
- Inal, M., Sunal, E., Kanbak, G., Zeytinoglu, S., Effects of postmenopausal hormone replacement and  $\alpha$ -tocopherol on the lipid profiles and antioxidant status **268**, 21
- Jensen, C.H., Krogh, T.N., Støving, R.K., Holmskov, U., Teisner, B., Fetal antigen 1 (FA1), a circulating member of the epidermal growth factor (EGF) superfamily: ELISA development, physiology and metabolism in relation to renal function **268**, 1
- Jiménez, C.V., see Ricós, C. **268**, 73
- Juvany, R., see Ricós, C. **268**, 73
- Kanbak, G., see Inal, M. **268**, 21
- King, A., see Thomas, L.A. **268**, 61
- Klempel, K., see Olesen, H. **268**, S5
- Krogh, T.N., see Jensen, C.H. **268**, 1
- Latimer, S., see Reglinski, J. **268**, 85
- Manns, M.P., see Schmidt, H.H.-J. **268**, 41
- Marcollet, M., see Minet, R. **268**, 121
- Maresch, L., see Vrecko, K. **268**, 31
- Meynial-Denis, D., see Minet, R. **268**, 121
- Minchinela, J., see Ricós, C. **268**, 73
- Minet, R., Villie, F., Marcollet, M., Meynial-Denis, D., Cynober, L., Measurement of glutamine

- synthetase activity in rat muscle by a colorimetric assay **268**, 121
- Mischak, I., see Vrecko, K. **268**, 31
- Murphy, G.M., see Thomas, L.A. **268**, 61
- Olesen, H., Cowan, D., Bruunshuus, I., Klempel, K., Hill, G., International Federation of Clinical Chemistry and International Union of Pure and Applied Chemistry. Properties and Units in the Clinical Laboratory Sciences. VI. Properties and Units in IOC Prohibited Drugs (IFCC-IUPAC Recommendations 1997) **268**, S5
- Paterson, D.E., see Reglinski, J. **268**, 85
- Perich, C., see Ricós, C. **268**, 73
- Porter, D., see Reglinski, J. **268**, 85
- Reglinski, J., Paterson, D.E., Latimer, S., Campbell, J.M., Wilson, R., Porter, D., Sturrock, R.D., Smith, W.E., Myocrisin-mediated oxidative stress **268**, 85
- Reibnegger, G., see Vrecko, K. **268**, 31
- Remaley, A., see Schmidt, H.H.-J. **268**, 41
- Ricós, C., Juvany, R., Jiménez, C.V., Perich, C., Minchinela, J., Hernández, A., Simón, M., Alvarez, V., Procedure for studying commutability validated by biological variation **268**, 73
- Scharpé, S., see Den Tandt, W.R. **268**, 107
- Schmidt, H.H.-J., Haas, R.E., Remaley, A., Genschel, J., Strassburg, C.P., Büttner, C., Manns, M.P., *In vivo* kinetics as a sensitive method for testing physiologically intact human recombinant apolipoprotein A-I: comparison of three different expression systems **268**, 41
- Simón, M., see Ricós, C. **268**, 73
- Smith, W.E., see Reglinski, J. **268**, 85
- Staedtler, P., see Vrecko, K. **268**, 31
- Støving, R.K., see Jensen, C.H. **268**, 1
- Strassburg, C.P., see Schmidt, H.H.-J. **268**, 41
- Sturrock, R.D., see Reglinski, J. **268**, 85
- Sunal, E., see Inal, M. **268**, 21
- Teisner, B., see Jensen, C.H. **268**, 1
- Templeton, D., see Cornelis, R. **268**, S75
- Thomas, L.A., King, A., French, G.L., Murphy, G.M., Dowling, R.H., Cholyglycine hydrolase and 7 $\alpha$ -dehydroxylase optimum assay conditions in vitro and caecal enzyme activities ex vivo **268**, 61
- Villie, F., see Minet, R. **268**, 121
- Vrecko, K., Staedtler, P., Mischak, I., Maresch, L., Reibnegger, G., Periodontitis and concentrations of the cellular immune activation marker neopterin in saliva and urine **268**, 31
- Wilson, R., see Reglinski, J. **268**, 85
- Zeytinoğlu, S., see Inal, M. **268**, 21

## Subject index

Volume 268 (1997)

- Amniotic fluid;** Kidney function; Circadian rhythm; ELISA; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268, 1**
- Baculovirus;** CHO cells; *E. coli*; Recombinant apoA-I; *In vivo* kinetics **268, 41**
- Cartilage;** Mud-pack therapy; Osteoarthritis; Cytokines **268, 101**
- Cellular immunity;** Periodontitis; CPITN; Immune activation; Neopterin **268, 31**
- Chitinase;** Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase; Lysozyme; Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase **268, 107**
- CHO cells;** *E. coli*; Baculovirus; Recombinant apoA-I; *In vivo* kinetics **268, 41**
- Cholylglycine hydrolase;** 7 $\alpha$ -Dehydroxylase; Deoxycholic acid; Gallstones **268, 61**
- Circadian rhythm;** Kidney function; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268, 1**
- Colorimetry;** Glutamine synthetase; Glutamyl transferase; Muscle **268, 121**
- Commutability;** Quality assurance; Transferability **268, 73**
- CPITN;** Periodontitis; Immune activation; Cellular immunity; Neopterin **268, 31**
- Cytokines;** Mud-pack therapy; Osteoarthritis; Cartilage **268, 101**
- 7 $\alpha$ -Dehydroxylase;** Cholylglycine hydrolase; Deoxycholic acid; Gallstones **268, 61**
- Deoxycholic acid;** Cholylglycine hydrolase; 7 $\alpha$ -Dehydroxylase; Gallstones **268, 61**
- E. coli*;** CHO cells; Baculovirus; Recombinant apoA-I; *In vivo* kinetics **268, 41**
- ELISA;** Kidney function; Circadian rhythm; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268, 1**
- Epidermal growth factor-like;** Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1 **268, 1**
- Fetal antigen 1;** Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Preadipocyte factor 1; Epidermal growth factor-like **268, 1**
- Gallstones;** Cholylglycine hydrolase; 7 $\alpha$ -Dehydroxylase; Deoxycholic acid **268, 61**
- Glutamine synthetase;** Glutamyl transferase; Muscle; Colorimetry **268, 121**

- Glutamyl transferase;** Glutamine synthetase; Muscle; Colorimetry **268, 121**
- Glutathione peroxidase;** Rheumatoid arthritis; Gold; Hydrogen peroxide; Monocytes **268, 85**
- Gold;** Rheumatoid arthritis; Hydrogen peroxide; Glutathione peroxidase; Monocytes **268, 85**
- Hydrogen peroxide;** Rheumatoid arthritis; Gold; Glutathione peroxidase; Monocytes **268, 85**
- Immune activation;** Periodontitis; CPITN; Cellular immunity; Neopterin **268, 31**
- In vivo kinetics;** CHO cells; *E. coli*; Baculovirus; Recombinant apoA-I **268, 41**
- Kidney function;** Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268, 1**
- Lipoprotein;** Postmenopausal; Transdermal oestradiol; Progesterone;  $\alpha$ -Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase **268, 21**
- Lysozyme;** Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase; Chitinase; Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase **268, 107**
- Malondialdehyde;** Postmenopausal; Transdermal oestradiol; Progesterone;  $\alpha$ -Tocopherol; Reduced glutathione; Superoxide dismutase; Lipoprotein **268, 21**
- Metabolic clearance rate;** Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268, 1**
- Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase;** Chitinase; Lysozyme; Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase **268, 107**
- Monocytes;** Rheumatoid arthritis; Gold; Hydrogen peroxide; Glutathione peroxidase **268, 85**
- Mud-pack therapy;** Osteoarthritis; Cytokines; Cartilage **268, 101**
- Muscle;** Glutamine synthetase; Glutamyl transferase; Colorimetry **268, 121**
- Neopterin;** Periodontitis; CPITN; Immune activation; Cellular immunity **268, 31**
- Osteoarthritis;** Mud-pack therapy; Cytokines; Cartilage **268, 101**
- Periodontitis;** CPITN; Immune activation; Cellular immunity; Neopterin **268, 31**
- Postmenopausal;** Transdermal oestradiol; Progesterone;  $\alpha$ -Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein **268, 21**
- Preadipocyte factor 1;** Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Epidermal growth factor-like **268, 1**
- Progesterone;** Postmenopausal; Transdermal oestradiol;  $\alpha$ -Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein **268, 21**
- Quality assurance;** Commutability; Transferability **268, 73**
- Recombinant apoA-I;** CHO cells; *E. coli*; Baculovirus; *In vivo* kinetics **268, 41**
- Reduced glutathione;** Postmenopausal; Transdermal oestradiol; Progesterone;  $\alpha$ -Tocopherol; Malondialdehyde; Superoxide dismutase; Lipoprotein **268, 21**
- Reference values;** Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268, 1**
- Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase;** Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase; Chitinase; Lysozyme **268, 107**
- Rheumatoid arthritis;** Gold; Hydrogen peroxide; Glutathione peroxidase; Monocytes **268, 85**
- Superoxide dismutase;** Postmenopausal; Transdermal oestradiol; Progesterone;  $\alpha$ -Tocopherol;



Malondialdehyde; Reduced glutathione; Lipoprotein 268, 21

**$\alpha$ -Tocopherol**; Postmenopausal; Transdermal oestradiol; Progesterone; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein 268, 21

**Transdermal oestradiol**; Postmenopausal; Progesterone;  $\alpha$ -Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein 268, 21

**Transferability**; Commutability; Quality assurance 268, 73